Assertio Therapeutics, Inc. (NasdaqGS: ASRT) related to the creation of a combined company between Assertio Therapeutics and Zyla Life Sciences. Under the terms of the agreement, Assertio Therapeutics will issue 2.5 shares to each Zyla stockholder. Assertio Therapeutics stockholders will own 68% and Zyla stockholders will own 32% of the combined company.